← Leaderboards
Jin Wang
Baylor College Of Medicine
$27,891,294
Attributed
$36,569,472
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,569,472 · 16
By mechanism
R01$23,115,069 · 11
U01$8,431,877 · 1
RF1$3,991,638 · 1
R21$762,030 · 2
K22$268,858 · 1
Top collaborators
- Hui Zheng9 shared
- Michael Wang8 shared
- Jennifer A. Woyach8 shared
- Xiongbin Lu2 shared
- Meng Carla Wang1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Timothy C Thompson$13,464,867
- David M Lonard$1,751,132
- Nancy Lynn Weigel$8,540,769
- Min Li$6,971,652
- Roshan Ailani$49,538
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoSuccessMouse ModelSignal TransductionProteinsPlayMolecularReportingPropertyPharmaceutical PreparationsPathway InteractionsCell SurvivalAlzheimer&AposOralRegulationBiologyCell DeathDesignLeadHalf-LifePlasmaMitochondriaMediating
Grant awards (77)
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$628,386
R01 · FY2025 · CA · contact PI
Regulation of Cell Death in HIV Reservoirs$575,980
R01 · FY2025 · AI · contact PI
Targeting the HIV-1 Reservoir in Myeloid Cells$483,639
R01 · FY2025 · MH · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$12,570
R01 · FY2025 · CA · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$804,669
U01 · FY2024 · AG · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$613,358
R01 · FY2024 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$610,105
R01 · FY2024 · CA · contact PI
Regulation of Cell Death in HIV Reservoirs$593,795
R01 · FY2024 · AI · contact PI
Targeting the HIV-1 Reservoir in Myeloid Cells$483,639
R01 · FY2024 · MH · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$119,583
R01 · FY2024 · CA · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$71,648
R01 · FY2024 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$68,584
R01 · FY2024 · CA · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$29,406
R01 · FY2024 · CA · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$1,023,733
U01 · FY2023 · AG · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2023 · CA · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$619,714
R01 · FY2023 · CA · contact PI
Regulation of Cell Death in HIV Reservoirs$609,170
R01 · FY2023 · AI · contact PI
Targeting the HIV-1 Reservoir in Myeloid Cells$483,639
R01 · FY2023 · MH · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$234,288
U01 · FY2023 · AG · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$125,150
R01 · FY2023 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$70,750
R01 · FY2023 · CA · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$2,219,336
U01 · FY2022 · AG · contact PI
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies$652,762
R01 · FY2022 · CA · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$628,719
R01 · FY2022 · CA · contact PI
Targeting the HIV-1 Reservoir in Myeloid Cells$483,639
R01 · FY2022 · MH · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$249,942
U01 · FY2022 · AG · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$72,195
R01 · FY2022 · CA · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$2,089,925
U01 · FY2021 · AG · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$641,550
R01 · FY2021 · CA · contact PI
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$572,529
R01 · FY2021 · CA · contact PI
Targeting the HIV-1 Reservoir in Myeloid Cells$483,639
R01 · FY2021 · MH · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$1,809,984
U01 · FY2020 · AG · contact PI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies$671,549
R01 · FY2020 · CA · contact PI
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$561,581
R01 · FY2020 · CA · contact PI
MOLECULAR REGULATION OF IMMUNITY TO VIRAL INFECTIONS$398,750
R01 · FY2020 · AI · contact PI
Molecular Regulation of Long-term Immune Memory$398,750
R01 · FY2020 · AI · contact PI
Targeting a lipid-mediated pro-longevity pathway as Alzheimer's therapy$48,650
RF1 · FY2020 · AG
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$453,641
R01 · FY2019 · CA · contact PI
Molecular Regulation of Long-term Immune Memory$398,750
R01 · FY2019 · AI · contact PI
MOLECULAR REGULATION OF IMMUNITY TO VIRAL INFECTIONS$398,750
R01 · FY2019 · AI · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$306,190
R01 · FY2019 · GM · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$115,103
R01 · FY2019 · GM · contact PI
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$65,784
R01 · FY2019 · CA · contact PI
Targeting a lipid-mediated pro-longevity pathway as Alzheimer's therapy$3,942,988
RF1 · FY2018 · AG
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$426,451
R01 · FY2018 · CA · contact PI
MOLECULAR REGULATION OF IMMUNITY TO VIRAL INFECTIONS$398,750
R01 · FY2018 · AI · contact PI
Molecular Regulation of Long-term Immune Memory$398,750
R01 · FY2018 · AI · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$306,190
R01 · FY2018 · GM · contact PI
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer$207,797
R21 · FY2018 · CA · contact PI
Drugging the Undruggable Coactivators using Small Molecule Inhibitors$427,784
R01 · FY2017 · CA · contact PI
MOLECULAR REGULATION OF IMMUNITY TO VIRAL INFECTIONS$398,750
R01 · FY2017 · AI · contact PI
Molecular Regulation of Long-term Immune Memory$398,750
R01 · FY2017 · AI · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$306,190
R01 · FY2017 · GM · contact PI
Engineering Antibody Drug Conjugates To Target P53-Defective Triple Negative Breast Cancer$185,933
R21 · FY2017 · CA · contact PI
Molecular regulation of immunity to viral infections$396,250
R01 · FY2016 · AI · contact PI
Molecular Regulation of Long-term Immune Memory$366,274
R01 · FY2016 · AI · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$306,190
R01 · FY2016 · GM · contact PI
Molecular Regulation of Long-term Immune Memory$32,272
R01 · FY2016 · AI · contact PI
REAL-TIME QUANTITATIVE IMAGING OF INTRACELLULAR BIOTHIOL DYNAMICS$306,190
R01 · FY2015 · GM · contact PI
Activation and in vivo Functions of Initiator Caspases$338,502
R01 · FY2012 · GM · contact PI
Activation and in vivo Functions of Initiator Caspases$338,502
R01 · FY2011 · GM · contact PI
Roles of Dendritic Cells in Immune Regulation$324,500
R01 · FY2011 · AI · contact PI
SELECTIVE MITOCHONDRIAL AUTOPHAGY IN THE MAINTENANCE OF GENOME STABILITY$198,106
R21 · FY2011 · CA · contact PI
Activation and in vivo Functions of Initiator Caspases$341,921
R01 · FY2010 · GM · contact PI
Roles of Dendritic Cells in Immune Regulation$327,777
R01 · FY2010 · AI · contact PI
SELECTIVE MITOCHONDRIAL AUTOPHAGY IN THE MAINTENANCE OF GENOME STABILITY$170,194
R21 · FY2010 · CA · contact PI
Activation and in vivo Functions of Initiator Caspases$345,375
R01 · FY2009 · GM · contact PI
Roles of Dendritic Cells in Immune Regulation$331,088
R01 · FY2009 · AI · contact PI
Roles of Dendritic Cells in Immune Regulation$331,088
R01 · FY2008 · AI · contact PI
Roles of Dendritic Cells in Immune Regulation$337,500
R01 · FY2007 · AI · contact PI
Activation and in vivo Functions of Initiator Caspases$321,078
R01 · FY2007 · AI · contact PI
Activation and in vivo Functions of Initiator Caspases$330,668
R01 · FY2006 · AI · contact PI
Activation and in vivo Functions of Initiator Caspases$338,625
R01 · FY2005 · AI
Activation and in vivo Functions of Initiator Caspases$338,625
R01 · FY2004 · AI
Activation and in vivo Functions of Initiator Caspases$169,313
R01 · FY2003 · AI
Roles of Dendritic Cell Apoptosis in Immune Tolerance$108,000
K22 · FY2002 · AI
Roles of Dendritic Cell Apoptosis in Immune Tolerance$160,858
K22 · FY2001 · AI